Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Pharmathene Inc (PIP)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [AMEX]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [AMEX]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
[[ ctrl.chartTitle ]]
Full Chart

Fundamentals

See More
  • Market Capitalization, $K 44,733
  • Shares Outstanding, K 68,820
  • Annual Sales, $ 5,230 K
  • Annual Income, $ 193,850 K
  • 36-Month Beta 2.43
  • Price/Sales 9.27
  • Price/Cash Flow 0.23
  • Price/Book 2.30
  • Price/Earnings ttm 0.24
  • Earnings Per Share ttm 2.95
  • Most Recent Earnings N/A on N/A
  • Next Earnings Date 05/08/17
  • Annual Dividend & Yield 0.00 (0.00%)
  • Most Recent Dividend 2.91 on 02/06/17
  • Sectors:

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.63 +3.17%
on 05/04/17
0.82 -20.73%
on 04/20/17
-0.14 (-17.72%)
since 04/04/17
3-Month
0.47 +38.30%
on 02/06/17
1.47 -55.78%
on 02/07/17
-2.65 (-80.30%)
since 02/03/17
52-Week
0.47 +38.30%
on 02/06/17
3.50 -81.43%
on 01/19/17
-1.74 (-72.80%)
since 05/04/16

Most Recent Stories

More News
PharmAthene and Altimmune Announce Combined Company Approved for Trading on Nasdaq Global Market

As previously announced, PharmAthene, Inc. (NYSE MKT:PIP) and Altimmune, Inc., a privately-held immunotherapeutics company targeting infectious diseases, have signed a definitive agreement for the merger...

PIP : 0.65 (-7.14%)
PharmAthene Announces Record Date and Meeting Date for Special Meeting of Stockholders Regarding Proposed Merger Transaction with Altimmune

PharmAthene, Inc. (NYSE MKT: PIP), a biodefense company developing medical countermeasures against anthrax, announced today that it has established a record date and meeting date for a special meeting...

PIP : 0.65 (-7.14%)
Altimmune to Present at the BIO CEO & Investor Conference

Altimmune, Inc., a clinical stage immunotherapeutics company targeting infectious diseases, announced today that Chief Executive Officer Bill Enright will present at the BIO CEO & Investor Conference on...

PIP : 0.65 (-7.14%)
Research Reports Coverage on Biotech Stocks -- PharmAthene, Corcept Therapeutics, Navidea Biopharma, and Inotek Pharma

Stock-Callers.com brings focus back on the Biotechnology industry to see how some equities have fared over the last few trading sessions. Under evaluation this morning are: PharmAthene Inc. (NYSE MKT:...

CORT : 12.97 (+0.15%)
ITEK : 1.00 (-2.91%)
PIP : 0.65 (-7.14%)
NAVB : 0.47 (unch)
Blog Coverage PharmAthene and Altimmune Announced a Merger; Set to Establish Immunotherapeutic Collaboration

Upcoming AWS Coverage on Celgene

CELG : 137.74 (+1.05%)
PIP : 0.65 (-7.14%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Sell with a Strongest short term outlook on maintaining the current direction.

Longer term, the trend strength is Strong. Long term indicators fully support a continuation of the trend.

The market is approaching oversold territory. Be watchful of a trend reversal.

See More

Business Summary

PharmAthene Inc. is a biodefense company formed to meet the critical needs of the United States by developing biodefense products. PharmAthene is dedicated to the rapid development of important and novel biotherapeutics to address biological pathogens and chemicals that may be used as weapons of bioterror....

See More

Support & Resistance

2nd Resistance Point 0.77
1st Resistance Point 0.71
Last Price 0.65
1st Support Level 0.61
2nd Support Level 0.57

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.